

General description

Dasatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias.

| | |
|--------------------|---|
| INN | Dasatinib |
| ATC codes | L01EA02 |
| Medicine type | Chemical agent |
| EML status history | First added in 2017 (TRS 1006) for Chronic myeloid leukaemia, not elsewhere classified |
| Wikipedia | Dasatinib  |
| DrugBank | Dasatinib  |

Recommendations

Section Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

